AUC | Cut-off | Sensitivity | Specificity | PPV | NPV | ||
---|---|---|---|---|---|---|---|
PE (n = 12) | PlGF | 0.697 | 133.8 | 75.0% | 76.3% | 50.0% | 90.6% |
sFLT-1 | 0.693 | 1171.5 | 91.7% | 52.6% | 37.9% | 95.3% | |
sFLT-1/PlGF ratio | 0.721 | 13.0 | 66.7% | 86.8% | 61.5% | 89.2% | |
EO PE (n = 9) | sFLT-1/PlGF ratio | 0.735 | 13.0 | 75.0% | 83.3% | 51.4% | 93.4% |
Gestational hypertension (n = 16) | PlGF | 0.494 | 117.6 | 37.5% | 70.6% | 37.5% | 70.6% |
sFLT-1 | 0.364 | 590.5 | 100.0% | 11.8% | 34.8% | 100.0% | |
sFLT-1/PlGF ratio | 0.456 | 2.3 | 100.0% | 8.8% | 34.0% | 100.0% | |
IUGR (n = 6) | PlGF | 0.640 | 262.3 | 100.0% | 38.6% | 18.2% | 100.0% |
sFLT-1 | 0.439 | 1751.0 | 50.0% | 63.6% | 15.8% | 90.3% | |
sFLT-1/PlGF ratio | 0.564 | 8.0 | 66.7% | 56.8% | 17.4% | 92.6% | |
Induced delivery < 34 weeks (n = 7) | PlGF | 0.834 | 133.8 | 85.7% | 72.1% | 33.3% | 96.9% |
sFLT-1 | 0.807 | 1850.5 | 85.7% | 74.4% | 35.3% | 97.0% | |
sFLT-1/PlGF ratio | 0.877 | 13.0 | 85.7% | 83.7% | 46.1% | 97.3% |